We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Some COVID-19 Vaccines Could Work Better on One Patient Population than Others, Says Dr. Anthony Fauci

By HospiMedica International staff writers
Posted on 29 Sep 2020
Among the four COVID-19 vaccines in the final stage of US clinical trials and another one about the enter Phase 3, few of them could hold promise in some patient populations better than others.

Speaking to Dr. More...
Howard Bauchner, editor of JAMA during a recent interview, Dr. Anthony Fauci who is the director of the National Institute of Allergy and Infectious Diseases, said that as the COVID-19 vaccines receive approval, researchers could discover that one works better on one population than others. The different COVID-19 vaccines will provide several options should one not be as effective as another.

The four COVID-19 vaccines that are in final-stage US clinical trials are being developed by Moderna, Pfizer, Johnson & Johnson and AstraZeneca. The fifth vaccine against COVID-19 from Novavax has begun Phase 3 clinical trials in the UK.

“There may be different vaccines for different situations,” Fauci told JAMA’s Bauchner. “You might find when you do a clinical trial, that you maybe have three or four vaccines that are effective.”

“But you may find one that does better in an older population than another,” Fauci added. “It could be that you would recommend, that if you are an older person you get this vaccine versus that. That is something we wish for namely that we have enough vaccines that you can tailor the better one for each individual group.”



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.